Synonyms: almonertinib | Ameile | Egfr T790M inhibitor HS-10296 | example 26 [WO2016054987A1] | HS10296
aumolertinib is an approved drug (China (2020))
Compound class:
Synthetic organic
Comment: Aumolertinib (a.k.a. almonertinib; HS-10296) is an orally bioavailable, third generation inhibitor of the receptor tyrosine kinase epidermal growth factor receptor (EGFR) with activity at the EGFRT790M mutant [1]. In assays using triple-negative breast cancer MDA-MB-231 cells, HS-10296 inhibits signalling via the EGFR/PI3K/AKT pathway which results in reduced proliferation and induction of autophagy and apoptosis. HS-10296 was developed by Hansoh Pharmaceutical, and ex-China rights were licensed to EQRx in mid-2020.
![]() Ligand Activity Visualisation ChartsThese are box plot that provide a unique visualisation, summarising all the activity data for a ligand taken from ChEMBL and GtoPdb across multiple targets and species. Click on a plot to see the median, interquartile range, low and high data points. A value of zero indicates that no data are available. A separate chart is created for each target, and where possible the algorithm tries to merge ChEMBL and GtoPdb targets by matching them on name and UniProt accession, for each available species. However, please note that inconsistency in naming of targets may lead to data for the same target being reported across multiple charts. ✖ |
|
References |
1. Yu H, Wei M, Cui Y, Sun X, Tong C, Sun G, Tan S, Ma J, Gao P, Liao J et al.. (2016)
Egfr inhibitor, and preparation and application thereof. Patent number: WO2016054987A1. Assignee: Shanghai Hansen Biomedical Technology Co, Jiangsu Hansen Pharmaceutical Group Co. Priority date: 11/10/2014. Publication date: 14/04/2016. |